- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02365233
Fatty Liver Study in Patients With Type II Diabetes
July 5, 2018 updated by: The University of Texas Medical Branch, Galveston
A Phase IV, Open Label, Randomized Trial on the Effect of Metformin Plus Lantus Insulin, Pioglitazone, or DPP4 Inhibitor on Fatty Liver in Patients With Type II Diabetes
The primary objective of this trial is to measure changes in hepatic lipid content using three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
In patients with type 2 diabetes whose glycemic control is not accomplished with Metformin alone, there are several options for additional hypoglycemic agent.
As per recent National guidelines at least three "second line" agents can be added to metformin: thiazolidinediones, Lantus insulin, and DPP4 inhibitors.
All three approaches have been proven to help accomplishing goals of therapy for glycemic control (HbA1c<7%) in clinical trials.
Whether one approach is superior to the other in improving associated non-glycemic metabolic abnormalities and risk for future morbidity and mortality in patients with type 2 diabetes remains a matter of intense debate.
Among these abnormalities, excessive triglyceride content in the liver (fatty liver or liver steatosis) is a major predictor of risk for non-alcoholic steato-hepatitis (NASH) and liver cirrhosis.
Fatty liver is highly prevalent in patients with type 2 diabetes.
There are no clinical studies done to determine if any of these three therapeutic options is superior at reducing the liver triglyceride content in patients with type 2 diabetes and fatty Liver.
Therefore, in this study we propose to measure and compare the effects on liver triglyceride content when either pioglitazone, lantus insulin, or DPP4 inhibitors are added to metformin in patients with poorly controlled type 2 diabetes (HbA1c>7.6%)
and fatty liver (presence of "bright" liver in abdominal ultrasound).
The primary objective of this trial is to measure changes in hepatic lipid content using three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Galveston, Texas, United States, 77555
- University of Texas Medical Branch -Galveston
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject has provided informed consent in a manner approved by the Institutional Review Board (IRB) and is willing and able to comply with the trial procedures.
- Adults at least 18 years of age at the time of consent.
- Have type 2 diabetes mellitus.
- Be on a stable medication with metformin (2000 mg/day) for at least 3 months prior to study enrollment.
- Have blood A1c >7.6% and < 8.5% within 3 months prior to study enrollment.
- Have fatty liver, which is diagnosed by ultrasonographic findings of "bright liver" within 1 year of study enrollment.
- Stable medication for lipid lowering, blood pressure control, dietary supplements, including vitamins, for at least 3 months.
- Women of Childbearing Potential must be willing and able to use acceptable forms of birth control while on the study.
Exclusion Criteria:
- Currently taking medication that can affect glucose metabolism other than Metformin.
- History of Kidney diseases that, in the opinion of the investigator , would place the subject at increased risk of participation or plasma levels of creatinine > 1.4 for women and > 1.5 for men.
- History of Cirrhosis of liver, hepatitis, or other liver diseases that, in the opinion of the investigator, would place the subject at increased risk of participation.
- Current alcohol consumption more than12 to 15 g of alcohol a day, or >12 oz of beer, 5 oz of wine, or 1.5 oz of distilled spirits.
- History of heart failure.
- Concurrent participation on another research study
- Use of an investigational agent in the 30 days prior to signing informed consent.
- History of prior non-compliance or the presence or history of psychiatric conditions (including drug or alcohol addiction) that would, in the opinion of the investigator, make it difficult for the subject to comply with the study procedures or follow the investigators instructions.
- Females who are pregnant or lactating
- Current Diagnosis or History of Bladder Cancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Thiazolidinedione
(Pioglitazone, 15 mg/day)
|
Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
Other Names:
|
ACTIVE_COMPARATOR: Lantus Insulin
0.35 U per kg body weight once daily
|
Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
Other Names:
|
ACTIVE_COMPARATOR: DPP4 inhibitor
Sitagliptin, 100 mg/day or Saxagliptin, 5 mg/day
|
Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Hepatic Lipid Content From Baseline Visit to Six Month Follow up Visit
Time Frame: Hepatic lipid content measurement will be taken on Day #1 ( the day of randomization) and at the 6 month follow up visit.
|
Comparison of the hepatic lipid content measurement taken by MRI at baseline with the measurement taken by MRI at the 6 month follow up visit.
|
Hepatic lipid content measurement will be taken on Day #1 ( the day of randomization) and at the 6 month follow up visit.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Nicola Abate, MD, University of Texas Medical Branch-Galveston
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 1, 2013
Primary Completion (ACTUAL)
December 31, 2016
Study Completion (ACTUAL)
December 31, 2016
Study Registration Dates
First Submitted
May 9, 2013
First Submitted That Met QC Criteria
February 17, 2015
First Posted (ESTIMATE)
February 18, 2015
Study Record Updates
Last Update Posted (ACTUAL)
July 31, 2018
Last Update Submitted That Met QC Criteria
July 5, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Liver Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Fatty Liver
- Non-alcoholic Fatty Liver Disease
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protease Inhibitors
- Incretins
- Insulin
- Insulin, Globin Zinc
- Insulin Glargine
- Pioglitazone
- Sitagliptin Phosphate
- Dipeptidyl-Peptidase IV Inhibitors
- Saxagliptin
Other Study ID Numbers
- 13-021
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type II Diabetes
-
Microbio Co LtdCompleted
-
pico-tesla Magnetic Therapies, LLCCompletedType II Diabetes MellitusUnited States
-
KeyBioscience AGEli Lilly and Company; Profil Institut für Stoffwechselforschung GmbH; Nordic...TerminatedType II Diabetes MellitusGermany
-
HealthInsightCenter for Technology and Aging; VoxivaUnknownType II Diabetes MellitusUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Khoo Teck Puat HospitalCompletedType II Diabetes in Subjects BMI 27 to 32Singapore
-
University of PretoriaNestlè Nutrition Institute Africa; South African Sugar AssociationCompletedDiabetes Mellitus, Type II [Non-insulin Dependent Type] [NIDDM Type] UncontrolledSouth Africa
-
University of PrimorskaUniversity of Ljubljana School of Medicine, SloveniaCompletedDiabetes Mellitus Type II,Slovenia
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
Clinical Trials on Pioglitazone
-
Dong-A ST Co., Ltd.CompletedType 2 DiabetesKorea, Republic of
-
Solvay PharmaceuticalsCompletedType 2 Diabetes MellitusUnited Kingdom
-
Emory UniversityCompletedDiabetic Ketoacidosis | Ketosis Prone Diabetes | Severe HyperglycemiaUnited States
-
University at BuffaloTakeda Pharmaceuticals North America, Inc.Completed
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceNot yet recruitingANCA Associated Vasculitis | Rapidly Progressive Glomerulonephritis | Crescentic Glomerulonephritis
-
National Cancer Institute (NCI)CompletedHead and Neck Cancer | Oral LeukoplakiaUnited States
-
University of Campinas, BrazilRecruitingMyocardial Reperfusion InjuryBrazil
-
West Virginia UniversityRecruitingBreast Cancer | Muscle FatigueUnited States
-
University of Texas Southwestern Medical CenterNational Institutes of Health (NIH)Completed
-
University of Texas Southwestern Medical CenterRecruitingNephrolithiasis, Uric AcidUnited States